Progression of macular atrophy after PDT combined with the COX-2 inhibitor Nabumetone in the treatment of neovascular ARMD.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

To evaluate photodynamic therapy (PDT) combined with the preferential the cyclooxygenase-2 (COX-2) inhibitor, nabumetone in the treatment of the neovascular age-related macular degeneration (ARMD).

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

Title: Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia

Publisher: Palacky University Olomouc

ISSN: 1213-8118

ISSN (Print): 1213-8118

Publication date (Electronic): 2014

Volume: 158

Issue: 1

Affiliations

[1 ] Department of Ophthalmology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic.

Article

DOI: 10.5507/bp.2012.066

PubMed ID: 23132511

SO-VID: 8e4b580c-f1cf-410f-98d4-0d376217a8d6

History

Data availability:

Comments

Comment on this article

scite_

Cited by 2

See all cited by